Clinical Trial Update: A 6-week Study to Evaluate the Safety and Efficacy of Quillichew ERCT in 4-5 Year Old Children With ADHD. [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating Quillichew ERCT in 4-5 year old children with ADHD was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Quillichew ERCT

Snippet

Sponsor: Pfizer | Conditions: Attention Deficit Hyperactivity Disorder (ADHD), Attention Deficit Hyperactivity Disorder | Phase 4 | Status: WITHDRAWN